Evidence map›Paper›PMID 33746212›Full record

ArticleProstate cancer and prostatic diseases2021

The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population.

H M Westgeest, M C P Kuppen, A J M van den Eertwegh, R de Wit, A M Bergman, R J A van Moorselaar, J L L M Coenen, A C M van den Bergh, D M Somford, N Mehra and 4 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. PSMA-RECAP: [Frontiers in oncology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

H M WestgeestDepartment of Internal Medicine, Amphia Hospital, Breda, the Netherlands. hwestgeest@amphia.nl.ORCID http://orcid.org/0000-0002-5735-3638
M C P KuppenInstitute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
A J M van den EertweghDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
R de WitDepartment of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.
A M BergmanDivision of Internal Medicine (MOD) and Oncogenomics, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
R J A van MoorselaarDepartment of Urology, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.
J L L M CoenenDepartment of Internal Medicine, Isala Klinieken, Zwolle, the Netherlands.
A C M van den BerghDepartment of Radiation Oncology, University Medical Center Groningen, Groningen, the Netherlands.
D M SomfordDepartment of Urology, Canisius Wilhemina Hospital, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-5277-6586
N MehraDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-4794-1831
I M van OortDepartment of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-8002-1869
K K H AbenDepartment for Health Evidence, Radboud University Medical Center, The Netherlands and Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands.
W R GerritsenDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-8754-1210
C A Uyl-de GrootInstitute for Medical Technology Assessment, Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.
Radboud University Nijmegen · NLAmsterdam University Medical Centers · NLErasmus University Rotterdam · NLCanisius-Wilhelmina Ziekenhuis · NLErasmus MC · NLErasmus MC Cancer Institute · NLIsala · NLThe Netherlands Cancer Institute · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2004 docetaxel was the first life-prolonging drug (LPD) registered for metastatic castration-resistant prostate cancer (mCRPC) patients. Between 2011 and 2014 new LPDs for mCRPC (cabazitaxel, abiraterone, enzalutamide, and radium-223) were introduced in the Netherlands. The objective of this study is to assess the impact of the introduction of new LPDs on treatment patterns and overall survival (OS) over time. PATIENTS AND

methodsCRPC patients diagnosed in the years 2010-2016 in the observational, retrospective CAPRI registry (20 hospitals) were included and followed up to 2018. Two subgroups were analyzed: treatment-naïve patients (subgroup 1, n = 3600) and post-docetaxel patients (subgroup 2, n = 1355).

resultsIn both subgroups, the use of any LPD increased: from 57% (2010-2011) to 69% (2014-2015) in subgroup 1 and from 65% (2011-2012) to 79% (2015-2016) in subgroup 2. Chemotherapy as first mCRPC-treatment (i.e., docetaxel) and first post-docetaxel treatment (i.e., cabazitaxel or docetaxel rechallenge) decreased (46-29% and 20-9% in subgroup 1 and 2, respectively), while the use of androgen-receptor targeting treatments (ART) increased from 11% to 39% and 46% to 64% in subgroup 1 and 2, respectively. In subgroup 1, median OS (mOS) from diagnosis CRPC increased from 28.5 months to 31.0 months (p = 0.196). In subgroup 2, mOS from progression on docetaxel increased from 7.9 months to 12.5 months (p < 0.001). After multiple imputations of missing values, in multivariable cox-regression analysis with known prognostic parameters, the treatment period was independent significant for OS in subgroup 1 (2014-2015 vs. 2010-2011 with HR 0.749, p < 0.001) and subgroup 2 (2015-2016 vs. 2011-2012 with HR 0.811, p = 0.037).

conclusionSince 2010, a larger proportion of mCRPC patients was treated with LPDs, which was related to an increased mOS.

Indexed as

AgedAged, 80 and overAndrostenesAntineoplastic Combined Chemotherapy ProtocolsBenzamidesChemoradiotherapyDocetaxelFollow-Up StudiesHumansMaleNitrilesPhenylthiohydantoinPrognosisProstatic Neoplasms, Castration-ResistantRadiumRetrospective StudiesabirateroneAndrostenesBenzamidescabazitaxelDocetaxelenzalutamideNitrilesPhenylthiohydantoinRadiumRadium-223Taxoids

Identifiers

PMID33746212
OpenAlexW3136168714

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.